Enfusion, Inc. (NYSE:ENFN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 7.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,029,366 shares of the company's stock after purchasing an additional 70,367 shares during the period. Geode Capital Management LLC owned approximately 0.80% of Enfusion worth $9,770,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Barclays PLC increased its holdings in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company's stock valued at $817,000 after purchasing an additional 61,554 shares in the last quarter. Wellington Management Group LLP increased its holdings in Enfusion by 6.7% in the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after buying an additional 61,032 shares in the last quarter. TenCore Partners LP acquired a new stake in shares of Enfusion during the 3rd quarter valued at approximately $3,938,000. State Street Corp boosted its stake in shares of Enfusion by 2.3% during the 3rd quarter. State Street Corp now owns 952,895 shares of the company's stock worth $9,043,000 after acquiring an additional 21,729 shares in the last quarter. Finally, Readystate Asset Management LP grew its holdings in shares of Enfusion by 173.7% in the 3rd quarter. Readystate Asset Management LP now owns 109,243 shares of the company's stock worth $1,037,000 after acquiring an additional 69,328 shares during the period. 81.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enfusion

In other news, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction on Friday, December 20th. The stock was sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the sale, the chief financial officer now owns 270,503 shares of the company's stock, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Neal Pawar sold 21,801 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at $11,469,746.32. This trade represents a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,918 shares of company stock worth $484,037. Corporate insiders own 36.44% of the company's stock.

Enfusion Trading Down 4.4 %

Shares of NYSE:ENFN traded down $0.45 on Thursday, hitting $9.85. The company had a trading volume of 371,299 shares, compared to its average volume of 392,888. The company has a market cap of $1.27 billion, a PE ratio of 246.31, a PEG ratio of 3.98 and a beta of 0.97. Enfusion, Inc. has a 52-week low of $7.52 and a 52-week high of $11.38. The business has a 50 day moving average of $9.97 and a 200 day moving average of $9.11.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Stifel Nicolaus boosted their target price on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, Enfusion currently has an average rating of "Hold" and a consensus price target of $10.25.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.